Philip Gregory, chief scientific officer at bluebird, said the latest analysis showed that the integration site of the vector was in a gene called VAMP4. bluebird bio's Philip Gregory ...

After an investigation in an adverse event, Bluebird Bio announced that it is “very unlikely” that the BB305 lentiviral vector (LVV) caused the case of acute myeloid leukemia (AML) which was ...

bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue c ...

Bluebird bio has now secured FDA approvals for two lentiviral vector gene therapies for rare diseases. Melissa Bonner, the company’s head of research, discusses the rocky road to success and ...

bluebird bio, Inc. ... bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies. May 02, 2017 08:00 AM Eastern Daylight Time.

Just weeks after two unexpected cases of blood cancer landed trials of its investigational gene therapies for sickle cell disease (SCD) and beta-thalassemia on FDA-issued clinical holds, Bluebird Bio ...

bluebird bio has acquired a Durham, NC, manufacturing facility from an undisclosed seller for $11.5M, to produce lentiviral vector for the company’s gene and cell therapies ...